NOTICIAS

Creditada a Conferência sobre SERIALIZAÇÃO

Creditada a Conferência sobre SERIALIZAÇÃO

O próximo 28 de Maio terá lugar a Conferência :Implicações da implementação em Portugal do ato delegado para a SERIALIZAÇÃO do MEDICAMENTO, bajo o lema : Qual é o melhor caminho para realizar a adequada implantação do sistema de serialização, de forma a garantir...

Draft guideline on clinical evaluation of vaccines – Revision 1

Draft guideline on clinical evaluation of vaccines – Revision 1

Summary This guideline addresses the clinical evaluation of vaccines intended for the prevention of infectious diseases. It includes considerations for trials intended to document the safety, immunogenicity and efficacy of new candidate vaccines and to support changes...

Clinical Trial Imaging Endpoint Process Standards Guidance for Industry

The purpose of this guidance is to assist sponsors in optimizing the quality of imaging data obtained in clinical trials intended to support approval of drugs and biological products. This guidance focuses on imaging acquisition, display, archiving, and interpretation...

Updated guidance: how to prepare a health claim application

Updated guidance: how to prepare a health claim application

EFSA has updated its advice for applicants on how to prepare and present a health claim application. The guidance presents a standardised format for a well-structured application. It also details the kind of information and data applicants need to submit in support of...

FDA Medical Devices Safety Action Plan

The Medical Device Safety Action Plan: Protecting Patients, Promoting Public Health outlines a vision for how FDA can continue to enhance our programs and processes to assure the safety of medical devices throughout the TPLC, to provide for the timely communication...

FDA NEW GUIDANCE on Special Protocol Assessment

This guidance provides information on the procedures and general policies adopted by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) for special protocol assessment (SPA). SPA is a process in which...

BENEFIT-RISK ASSESSMENT IN DRUG REGULATORY DECISION-MAKING

Draft PDUFA VI Implementation Plan (FY 2018-2022) MARCH 30, 2018 U.S. FOOD AND DRUG ADMINISTRATION   As part of the sixth authorization of the Prescription Drug User Fee Act (PDUFA VI) under Title 1 of the FDA Reauthorization Act of 2017, FDA committed to...

Conclusões da 3ª edição do curso “QUALIFIED PERSON”

Conclusões da 3ª edição do curso “QUALIFIED PERSON”

A Formiventos celebrou no dia 23 de maio a 2ª Edição do Curso : QUALIFIED PERSON , conduzido pela reputada especialista Dra Fernanda Ralha, Diretora. Direçaõ de inspeção e Licenciamento do INFARMED; bajo o lema "Uma revisão do impacto das novas Regulamentações nas...

The MHRA has published its ‘GxP data integrity guide’

The MHRA has published its ‘GxP data integrity guide’

The way regulatory data is generated has continued to evolve in line with the ongoing development of supporting technologies such as the increasing use of electronic data capture, automation of systems and use of remote technologies; and the increased complexity of...

Submitting risk management plans on the new EU template: 3 tips

Submitting risk management plans on the new EU template: 3 tips

Published  by pharmaphorum.com Are you prepared for the upcoming changeover to the new EU risk management plan (RMP) template? Seema Jaitly offers some timely guidance on the new EU RMP document. DOWNLOAD About the author: Dr Seema Jaitly qualified in Medicine from...

RESUMO DA 2ª EDIÇÃO DO REGULATORY DAY

RESUMO DA 2ª EDIÇÃO DO REGULATORY DAY

No passado dia 27 de Fevereiro teve lugar o 2º Fórum The Regulatory Community in Action, no hotel Novotel, onde participaram mais de 60 participantes com largo conhecimento e experiência na área regulamentar da Indústria Farmacêutica. Com uma plateia repleta e com...

New guidance on processing of applications for regulated products

New guidance on processing of applications for regulated products

An administrative guidance published today sets out the principles that EFSA follows when processing applications for regulated products. This is part of EFSA’s continuous efforts to support applicants throughout the life-cycle of their applications. The guidance...

DATA INTEGRITY REFERENCES

REFERÊNCIAS: .-EMA: Questions and answers: Good manufacturing practice - Data Integrity Section .-FDA: FDA Data Integrity Guidance .-MHRA: MHRA Data Integrity Definitions and Guidance .-PIC/S: PIC/S Guidance .-WHO: WHO Guidance